New Patent Broadens Advanced Catheter Engineering, Inc.'s Intellectual Property Portfolio

Apr 10, 2001, 01:00 ET from Advanced Catheter Engineering, Inc.

    LIVERMORE, Calif., April 10 /PRNewswire/ -- Advanced Catheter Engineering,
 Inc. (ACE, Inc.) today announced that the United States Patent and Trademark
 Office has issued patent number 6,214,024 entitled, "Tissue Cutting Catheter
 and RF Cutting Method."  The broad claims of this patent focus on linear RF
 incisions from the side of the catheter, with or without therapeutic infusion
 at the treatment site.  The utility of the device is not limited to
 cardiovascular applications.  Additional potential applications include drug
 delivery, percutaneous myocardial revascularization (PMR), tissue biopsy and
 tumor treatment devices.
     ACE, Inc. President and CEO Russ Houser stated, "This new patent, combined
 with the previously issued, "Tissue Removing Catheter and RF Cutting Method"
 (5,876,369) patent provides very broad independent device and process claims
 coverage."  Mr. Houser continues, "These issued patents also provide a
 protective "firewall" around the related technologies in pending cases."
     The Company also announced the recent publication of PCT No. WO 01/10287.
 This case describes a surgical and catheter-based percutaneous myocardial
 revascularization (PMR) device featuring much easier, quicker and more
 repeatable catheter placement than designs currently on the market.  This
 device cuts (mechanically, and/or thermally) from the side of the catheter.
 Multiple additional applications include drug/gene therapy infusion (including
 electroporation method) and electrophysiology, including atrial fibrillation
 (AF), ventricular tachycardia (VT), and ventricular fibrillation (VF).  This
 case is a continuation-in-part (CIP) of patent numbers 6,214,024, 5,876,369
 and 5,665,062.
     The above technologies are currently available to license or co-develop.
 
     About Advanced Catheter Engineering, Inc.
     ACE, Inc. is a privately held biomedical device development company,
 specializing in the creation of cutting edge surgical and catheter-based
 technologies.  ACE, Inc. assists American and European companies of all sizes,
 as well as individuals (including physicians, engineers, and entrepreneurs).
 Services focus on three specific areas:  intellectual property, prototype
 development, and start-up company fundraising.
     Mr. Houser has assumed the responsibilities of Chairman of the Board of
 Directors effective March 1, 2001.  Prior to joining ACE, Inc., Mr. Houser was
 the Founder, Director & Chief Technical Officer of Converge Medical, Inc.,
 formerly Advanced Bypass Technologies, Inc. of Pleasanton, California.
     For inquiries, contact Russ Houser at Advanced Catheter Engineering, Inc.
 at 925-371-1946 or by e-mail at:  rh@advcatheng.com.
 
     For further background information, as well as additional technology
 available for licensing, please visit the Advanced Catheter Engineering, Inc.
 website at:  http://www.advcatheng.com .
 
 

SOURCE Advanced Catheter Engineering, Inc.
    LIVERMORE, Calif., April 10 /PRNewswire/ -- Advanced Catheter Engineering,
 Inc. (ACE, Inc.) today announced that the United States Patent and Trademark
 Office has issued patent number 6,214,024 entitled, "Tissue Cutting Catheter
 and RF Cutting Method."  The broad claims of this patent focus on linear RF
 incisions from the side of the catheter, with or without therapeutic infusion
 at the treatment site.  The utility of the device is not limited to
 cardiovascular applications.  Additional potential applications include drug
 delivery, percutaneous myocardial revascularization (PMR), tissue biopsy and
 tumor treatment devices.
     ACE, Inc. President and CEO Russ Houser stated, "This new patent, combined
 with the previously issued, "Tissue Removing Catheter and RF Cutting Method"
 (5,876,369) patent provides very broad independent device and process claims
 coverage."  Mr. Houser continues, "These issued patents also provide a
 protective "firewall" around the related technologies in pending cases."
     The Company also announced the recent publication of PCT No. WO 01/10287.
 This case describes a surgical and catheter-based percutaneous myocardial
 revascularization (PMR) device featuring much easier, quicker and more
 repeatable catheter placement than designs currently on the market.  This
 device cuts (mechanically, and/or thermally) from the side of the catheter.
 Multiple additional applications include drug/gene therapy infusion (including
 electroporation method) and electrophysiology, including atrial fibrillation
 (AF), ventricular tachycardia (VT), and ventricular fibrillation (VF).  This
 case is a continuation-in-part (CIP) of patent numbers 6,214,024, 5,876,369
 and 5,665,062.
     The above technologies are currently available to license or co-develop.
 
     About Advanced Catheter Engineering, Inc.
     ACE, Inc. is a privately held biomedical device development company,
 specializing in the creation of cutting edge surgical and catheter-based
 technologies.  ACE, Inc. assists American and European companies of all sizes,
 as well as individuals (including physicians, engineers, and entrepreneurs).
 Services focus on three specific areas:  intellectual property, prototype
 development, and start-up company fundraising.
     Mr. Houser has assumed the responsibilities of Chairman of the Board of
 Directors effective March 1, 2001.  Prior to joining ACE, Inc., Mr. Houser was
 the Founder, Director & Chief Technical Officer of Converge Medical, Inc.,
 formerly Advanced Bypass Technologies, Inc. of Pleasanton, California.
     For inquiries, contact Russ Houser at Advanced Catheter Engineering, Inc.
 at 925-371-1946 or by e-mail at:  rh@advcatheng.com.
 
     For further background information, as well as additional technology
 available for licensing, please visit the Advanced Catheter Engineering, Inc.
 website at:  http://www.advcatheng.com .
 
 SOURCE  Advanced Catheter Engineering, Inc.